H.C. Wainwright lowered the firm’s price target on Apollomics to $5 from $17 and keeps a Buy rating on the shares. The new target reflects the financial overhang for Apollomics, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLM:
- Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
- Apollomics reports FY23 EPS ($2.32) vs ($8.44) last year
- Apollomics appoints Plunkett as CFO
- Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
- Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
